U. S.  Securities and Exchange Commission
                       Washington, D.C. 20549

           Form 10-QSB -- Quarterly or Transitional Report
           (Added by 34-30968, eff.  8/13/93, as amended)


(Mark One)
[ X ]  Quarterly Report Under Section 13 or 15(d) of the Securities 
       Exchange Act of 1934  

For the quarterly period ended March 31, 1997                

[   ]   Transition Report Under Section 13 or 15(d) of the Securities 
        Exchange  Act of 1934   

For the transition period from	to	________________ to _________________

Commission file number 0-17032

                        PROTEIN DATABASES, INC.		
-----------------------------------------------------------------
(Exact name of small business issuer as specified in its charter)   

Delaware                             13-3186604
---------------------------------    -----------------
(State or other jurisdiction of      (I.R.S. Employer 
 incorporation or organization)      Identification No.)

405 Oakwood Road, Huntington Station, New York    11746
----------------------------------------------    ----------
(Address of principle executive offices)          (Zip Code) 

(516) 673-3939 
-------------------------
Issuer's telephone number
 
(Former name, former address and former fiscal year, 
 if changed since last report)
-----------------------------------------------------
Check whether the issuer (1) filed all reports required to be filed by 
Section 13 or 15(d) of the Exchange Act during the past 12 months 
(or for such shorter period that the registrant was required to file 
such reports), and (2) has been subject to such filing requirements for 
the past 90 days. Yes   x   .  No___.

State the number of shares outstanding of each of the issuer's classes 
of common equity, as of the latest practicable date.

Class                                  Outstanding at April 30, 1997
---------------------------            -----------------------------
Common Stock $.01 par value            1,459,724

<PAGE>

                            PROTEIN DATABASES, INC.

                                BALANCE SHEET

                                March 31,1997
                                ( UNAUDITED )


ASSETS



CURRENT ASSETS:

Cash and cash equivalents          $305,558
Accounts receivable                 137,186 
Inventory                            52,514
Prepaid expenses                     10,623
                                   --------
Total current assets                505,881 
				

PROPERTY AND EQUIPMENT-NET          199,895

OTHER ASSETS                          9,020
                                   --------

TOTAL                              $714,796
                                   ========


                    LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
  Accounts payable                  $56,559 
  Accrued expenses                   54,136 
  Unearned revenue                   36,199
                                   -------- 
  Total current liabilities         146,894 


STOCKHOLDERS' EQUITY:
  Common stock                       14,597 
  Additional paid-in capital      8,519,636 
  Accumulated deficit            (7,966,331)
                                 ----------
Stockholders' Equity                567,902
                                 ----------

TOTAL                              $714,796
                                 ==========

<PAGE>

                        PROTEIN DATABASES, INC.

                  CONDENSED STATEMENTS OF OPERATIONS
                            ( UNAUDITED )

                                   For the Three Months
                                     Ended March 31,
                                   --------------------
                                   1997            1996
                                   ----            ----

Revenues                       $534,952        $361,913 


Expenses
  Cost of sales                  94,278         175,962
  General and administrative    153,873         158,194
  Marketing and sales           136,290         200,626
  Research and development      101,181         150,723
                                -------         -------
  Total expenses                485,622         685,505
                                -------         -------

Net income (loss)               $49,330       $(323,592)
                                =======        ========

Net income (loss) 
  per common share                 $.03$           (.22)
                                =======        ========

Weighted average number of shares
  used in computing earnings per share

                              1,459,724       1,459,724
                              =========       =========

<PAGE>

                         PROTEIN DATABASES, INC.

                    CONDENSED STATEMENTS OF CASH FLOWS
                              ( UNAUDITED )

                                     For the Three Months
                                       Ended March 31,
                                     --------------------
                                     1997            1996
                                     ----            ----

Cash flow from operations:
  Net income (loss)               $49,330       ($323,592)
  Adjustments to reconcile 
    net income to net cash 
    provided by 
    (used in) operations:

  Depreciation and amortization	   24,000          24,000
  Changes in operating assets 
  and liabilities:

  Accounts receivable             227,469         161,971
  Inventory                         6,471           7,368 
  Other current assets                378               0
  Prepaid expenses                      0           2,507
  Accounts payable and 
    accrued expenses             (114,097)        (64,817)
  Unearned revenue                 (6,387)         12,117
                                 --------        --------
  Net cash provided by operations 187,164        (180,446)
                                 ========        ========

Cash flows from investments in
  property and equipment, net       (958)         (20,606)
                                 --------        --------

Increase (decrease) in cash      186,206         (201,052)
                                 --------        --------

Cash and cash equivalents, 
  beginning of period            119,352          778,718
                                --------         --------
Cash and cash equivalents, 
  end of period                 $305,558         $577,666
                                ========         ========

<PAGE>
                                       						 ( Unaudited )
 
                      PROTEIN DATABASES, INC.	

                    NOTES TO FINANCIAL STATEMENTS

                          MARCH 31, 1997

NOTE 1 - GENERAL:

The accompanying unaudited financial statements include all adjustments, 
consisting of normal recurring accruals, which are, in the opinion of 
management, necessary for a fair statement of the results of the interim 
periods.  The statements have been prepared in accordance with the 
requirements for quarterly reports on Form 10-QSB and, therefore, do not 
include all disclosures or financial details required by generally 
accepted accounting principles.  These condensed financial statements 
should be read in conjunction with the financial statements and the notes
thereto included in the Company's Annual Report on Form 10-KSB for the 
year ended December 31, 1996.

The results of operations for the interim periods are not necessarily 
indicative of results to be expected for a full year's operations.

<PAGE>

PROTEIN DATABASES, INC.

Management's Discussion and Analysis of Operations

Liquidity and Capital Resources

The Company's present liquidity position is critical.  
During the year ended December 31, 1996, the Company had a net loss from 
operations of $811,323.  As of March 31, 1997, the Company's total 
current assets were $505,881 (including cash of $305,558) and its total 
liabilities were $146,894 (see accompanying Balance Sheet).

Management currently believes that the Company will require additional 
product sales or funding during, or shortly after the end of, the quarter
ending June 30, 1997 to continue its operations.

The Company is substantially dependent upon distributors for the sale of 
its products outside of the United States.

On April 19, 1996, Pharmacia Biosystems B.V. and Pharmacia Biotech A.B.
("Pharmacia"), the most significant worldwide distributor of the 
Company's products, elected not to renew its contract to distribute the 
Company's products.

On April 8, 1997, the Company announced that it had entered into a 
letter of intent to sell all of its intellectual property, fixed assets 
and property, plant and equipment for $1 million.  The transaction is 
subject to the buyer's completion of due diligence, the approval of the 
board of directors of the buyer, the approval of the Company's board of 
directors and shareholders and certain other conditions.  The Company 
does not anticipate this sale to be consummated prior to June 30, 1997.

As a result of the limited amount of funds currently available to finance
the Company's operations, the report of the Company's independent 
Certified Public Accountants on the Financial Statements as of December 
31, 1996 contains an explanatory paragraph indicating that there is 
substantial doubt about the Company's ability to continue as a going 
concern.

The Company had no material commitments for capital equipment additions
at March 31, 1997.

Revenues

The Company generates revenues primarily by selling software systems
and,to a lesser extent, from contract research and development, royalties
and other income sources.  

Software systems revenues include revenues from the sale of the Company's
proprietary software, Original Equipment Manufacturers (OEM) equipment,
software maintenance and software updates.  Software systems revenues
include sales of OEM equipment that cost $49,903 as compared with 
$106,092 of such cost in the first quarter of 1997 and 1996, 
respectively.  The Company obtains its principal OEM equipment from a 
limited number of suppliers.  If the Company were unable to continue to 
obtain the equipment on reasonable terms from its current suppliers, or
from alternate sources, the Company would be materially and adversely
affected.

<PAGE>

                      PROTEIN DATABASES, INC.
  --------------------------------------------------------------
  Management's Discussion and Analysis of Operations (Continued)

Excluding the cost of OEM equipment, the Company's Software systems
revenues increased 90% in the first quarter of 1997 from the first 
quarter of 1996.  The increase was primarily due to a non-recurring 
increase in the number of products sold under the Company's distribution
agreement, as amended, with Toyobo Co. Ltd. ("Toyobo"), the exclusive 
distributor of the Company's products in Japan.  1997's revenues include
approximately $280,000 of revenue from Toyobo, which amount essentially
constitutes all of Toyobo's purchase commitments from the Company for
1997.

Expenses

After excluding the decrease in cost of OEM equipment of $56,189 in the 
three months ended March 31, 1997 from the comparable period in the prior
year, the Company's cost of sales decreased by $25,195 between the 
periods as a result of lower costs for supplies and equipment and one 
less employee in the department.

The Company's sales and marketing expenses decreased in the three months
ended March 31, 1997 from the comparable period in the prior year
principally as a result of lower salary and related expenses, due to 
two less employees, and lower costs for supplies, travel and promotional
expenses.

The decrease in the Company's research and development expenses in the
three months ended March 31, 1997 from the comparable period in the prior
year was primarily attributable to a decrease of two employees in the 
department and lower costs for supplies and travel expenses.  

<PAGE>

Part II - Other Information

Item 6.	Exhibits and Reports on Form 8-K

        ( a ) 	 Exhibits: EX-27.

        ( b )   Reports on Form 8-K:  There were no reports on
                Form 8-K filed by the Company during the three months
                ended March 31, 1997.

<PAGE>

Signatures


In accordance with the requirements of the Securities and Exchange Act of
1934, the registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.




 
                                     Protein Databases, Inc.			
                                     -----------------------
                                         (Registrant)



Dated May 9, 1997                   S/Stephen H. Blose
                                      Stephen H. Blose
                                      Director, President and
                                      Chief Executive Officer



Dated May 9, 1997                   S/Alan P. Chodosh
                                      Alan P. Chodosh
                                      Vice President of Finance
                                      (Principal Financial and
                                       Accounting Office)